Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.Įstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Revenues are expected to be $112.75 million, up 11.4% from the year-ago quarter. This cancer test maker is expected to post quarterly earnings of $0.38 per share in its upcoming report, which represents a year-over-year change of +8.6%. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. On the other hand, if they miss, the stock may move lower. The earnings report might help the stock move higher if these key numbers are better than expectations. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The market expects Genomic Health to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2019.
0 kommentar(er)
